Interestingly, it should be noted that although the drugs marketed so far do not improve the symptoms of AD, the study of new drugs with anticholinesterase and butyrylcholinesterase action remains key, since a deficit of ACh has been demonstrated in AD. Here, BCHE is linked to Alzheimer disease.